SEC Form 4 · accession 0001209191-15-059099
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Bigham
Officer — Chairman and CEO · Director
Period of report
Jun 30, 2015
Accepted (ET)
Jul 2, 2015 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2015 | A | 50,000 | $0.00 | A | 50,000 | D | |
| Common StockF1,F2 | holding | — | — | — | 1,301,413 | I | By Abingworth Bioventures VI LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $25.77 | Jun 30, 2015 | A | 100,000 | A | — | Jun 29, 2025 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The shares are held by Abingworth Bioventures VI, LP ("ABV VI"). The investment manager of ABV VI is Abingworth LLP, or Abingworth. Abingworth Bioventures VI GP LP, or Abingworth GP, serves as the general partner of ABV VI. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth GP (acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth all investment and dispositive power over the shares held by ABV VI.
- F2The Reporting Person is part of an investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. The Reporting Person disclaims beneficial ownership of all shares held of record by ABV VI. This report shall not be deemed an admission that the Reporting Person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
- F4The shares shall vest in 36 equal monthly installments measured commencing from June 30, 2015.